All In MedTech

FDA Clearance Tracker · P860004-S387

SynchroMed® Infusion System, Ascenda® Intrathecal Catheters

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Sep 2, 2022 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

Sep 2, 2022

Approved

Time to decision

206 days

Received Feb 8, 2022. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Normal 180 Day Track

Device class

Class III

The decision

FDA number
P860004-S387
Device name
SynchroMed® Infusion System, Ascenda® Intrathecal Catheters
Applicant location
Minneapolis, MN
Received
Feb 8, 2022
Decided
Sep 2, 2022
Decision
Approved
Supplement type
Normal 180 Day Track
Reason for supplement
Change Design/Components/Specifications/Material
Original approval
P860004

Device type

Device class
Class III

Every decision under product code LKK

FDA's approval statement

As written in FDA's record.

Approval for a change in the formulation of the resin used in the plastic hub component (Styrene-Butadiene Copolymer), and replacement of the current Urethane Acrylate adhesive (Dymax 1136-M) with another Urethane Acrylate adhesive (Dymax 1405-M-UR-SC), which is used to attach the cannula to the hub.

Source documents

Other decisions for Medtronic, Inc.

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

5 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.